AKBL.F Stock Overview
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ALK-Abelló A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.18.50 |
52 Week High | kr.19.90 |
52 Week Low | kr.8.20 |
Beta | 0.44 |
1 Month Change | 6.87% |
3 Month Change | 39.62% |
1 Year Change | n/a |
3 Year Change | -95.23% |
5 Year Change | -88.75% |
Change since IPO | -83.18% |
Recent News & Updates
Recent updates
Shareholder Returns
AKBL.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -0.3% | 0.5% |
1Y | n/a | 22.4% | 29.0% |
Return vs Industry: Insufficient data to determine how AKBL.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AKBL.F performed against the US Market.
Price Volatility
AKBL.F volatility | |
---|---|
AKBL.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKBL.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AKBL.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1923 | 2,824 | Peter Halling | https://www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
ALK-Abelló A/S Fundamentals Summary
AKBL.F fundamental statistics | |
---|---|
Market cap | US$4.17b |
Earnings (TTM) | US$70.84m |
Revenue (TTM) | US$703.17m |
58.8x
P/E Ratio5.9x
P/S RatioIs AKBL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AKBL.F income statement (TTM) | |
---|---|
Revenue | kr.4.82b |
Cost of Revenue | kr.1.79b |
Gross Profit | kr.3.04b |
Other Expenses | kr.2.55b |
Earnings | kr.486.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
Earnings per share (EPS) | 2.20 |
Gross Margin | 62.94% |
Net Profit Margin | 10.07% |
Debt/Equity Ratio | 10.4% |
How did AKBL.F perform over the long term?
See historical performance and comparison